BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $42.60 Consensus Price Target from Brokerages
Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and […]
Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and […]
